Research Article

Application of Jianpi Xiaoi Recipe Combined with Cisplatin and Adriamycin in the Treatment of Endometrial Cancer and Its Effect on Disease Control Rate

Li Ding,¹ Hongyu Li,² and Yuping Wang³

¹Department of Gynaecology, People's Hospital of Rizhao, Rizhao 276826, Shandong, China

²Department of Radiology, People's Hospital of Lixia District, Jinan 250013, Shandong, China

³Department of Postpartum Rehabilitation, Zibo City Maternal and Child Health Care Hospital, Zibo 250031, Shandong, China

Correspondence should be addressed to Yuping Wang; sdzfwyp@163.com

Received 25 August 2021; Accepted 14 September 2021; Published 28 September 2021

Academic Editor: Muhammad Wasim Khan

Copyright © 2021 Li Ding et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To explore the application of Jianpi Xiaoi recipe combined with cisplatin and Adriamycin in the treatment of endometrial cancer (EC) and its effect on the disease control rate (DCR). **Methods.** The data of 120 EC patients treated in People's Hospital of Rizhao from February 2019 to February 2020 were retrospectively analyzed. They were equally split into experimental group and control group according to the order of admission. All patients were treated with neoadjuvant intra-arterial chemotherapy (continuous infusion of the uterine artery for 5 days before surgery, with 20 mg of cisplatin mixed with 2000 mg of normal saline and 10 mg of Adriamycin mixed with 500 ml of normal saline daily), while the experimental group was treated with Jianpi Xiaoi recipe at the same time to compare the short-term efficacy, immune function indexes, incidence of adverse reactions, and HEC-1-B (human endometrial adenocarcinoma cells) cell inhibition rates between the two groups. **Results.** The DCR and objective remission rate (ORR) in the experimental group were markedly higher compared with the control group ($P < 0.05$). The immune function indexes after treatment were remarkably better in the experimental group than in the control group ($P < 0.05$). Compared with the control group, the incidence of adverse reactions in the experimental group was notably lower ($P < 0.05$), while the HEC-1-B inhibition rates after treatment were obviously higher ($P < 0.05$). **Conclusion.** Jianpi Xiaoi recipe combined with cisplatin and Adriamycin can increase the HEC-1-B cell inhibition rate in EC patients, improve their immune function, reduce the possibility of adverse reactions, and enhance the therapeutic effect, which is worthy of clinical application and popularization.

1. Introduction

Endometrial cancer (EC) is an epithelial malignant tumor that occurs in the endometrium. According to the statistics from the American Cancer Society (ACS) in 2017, EC is the sixth most common female cancer, with the highest incidence in South America, Northern Europe, and Eastern Europe during 2006–2007. The risk of EC in Southeast Asia has surged in the past decade, with an increasing incidence in Japan, Singapore, and the Philippines year by year [1]. The EC incidence in China has also reached 10/100,000, becoming a female reproductive system malignant tumor only after cervical cancer [2]. Since the early symptoms of the

disease are not obvious, and patients often suffer from symptoms such as vaginal bleeding, menstrual disorders, and lumbar-abdominal pain only after the disease progresses [3, 4], the diagnosis time of EC is often late and application of chemotherapy will cause serious adverse reactions due to gradually reduced immune function of patients [5, 6], affecting the overall therapeutic effect. Therefore, the selection of appropriate drugs to meet the maximum killing effect of cancer cells while minimizing its toxicity to normal cells has become the focus of the studies on chemotherapy.

Previous studies have shown that neoadjuvant intra-arterial chemotherapy (cisplatin and Adriamycin) has a remarkable effect on cervical cancer [7], Nasioudis et al.

applied it in the treatment of EC and found that this chemotherapy regimen can effectively reduce the mass volume and eliminate the possibility of subclinical metastasis [8]. A large number of international documents have confirmed that cisplatin and Adriamycin, like other antitumor drugs, kill cancer cells by inducing specific target molecule damage or dysfunction [9]. Although some studies have shown that they are safe and can reduce the incidence of complications in the subsequent surgery [10, 11], their effect on the incidence of adverse reactions in EC patients remains unclear. In recent years, Sugandha et al. found that based on the conventional chemotherapy regimens, dialectical application of Jianpi Xiaoi recipe can increase the disease control rate (DCR) of patients with advanced metastatic colorectal cancer and reduce the possibility of adverse reactions [11]. From the perspective of modern pharmacology, Jianpi Xiaoi recipe can also play a significant role in the treatment of EC because its components such as ginseng, *Astragalus*, poria, progesterone, and ginsenoside Rg3 can not only regulate the immune function of patients but also block the iron transport pathways of human endometrial adenocarcinoma cells (HEC-1-B), thus inducing apoptosis of cancer cells by inhibiting HEC-1-B and enhancing the therapeutic effect [12]. Therefore, this paper combined Jianpi Xiaoi recipe with cisplatin and Adriamycin to explore the application effect on EC patients, reported as follows.

2. Materials and Methods

2.1. Study Design. This retrospective study was conducted in People's Hospital of Rizhao from February 2019 to February 2020, aiming to explore the application of Jianpi Xiaoi recipe combined with cisplatin and Adriamycin in the treatment of endometrial cancer (EC) and its effect on the DCR.

2.2. Enrollment of Research Subjects. The data of 120 EC patients treated in People's Hospital of Rizhao from February 2019 to February 2020 were retrospectively analyzed. Patients were included according to the following criteria: (1) the patients were diagnosed with EC by preoperative fractional curettage pathology and postoperative pathological examination and met the diagnostic criteria in *Guidelines for the Diagnosis and Treatment of Endometrial Cancer (the 4th Edition)* [13]; (2) the patient had a good physical condition and could tolerate radiotherapy, chemotherapy, and surgical treatment; (3) the patients had no allergic reactions to the drugs involved in this study; and (4) the patients were expected to survive more than 3 months. Patients were excluded according to the following criteria: (1) the patients who were unable to communicate with others due to hearing impairment, language impairment, unclear consciousness, or mental illness; (2) the patients who quite the treatment halfway, died, changed the treatment regimens, and could not be followed up; (3) the patients complicated with serious heart, brain, liver, and kidney diseases or other malignant tumors; (4) the patients with incomplete clinical data; (5) the patients with low treatment

compliance; (6) the patients in pregnancy and lactation; and (7) the patients who were treated in other medical institutions or participated in similar studies.

2.3. Steps. One hundred and twenty patients were enrolled in this study and were equally split into experimental group and control group according to the order of admission. On the day when the patients agreed to participate in the study, the research team collected their sociodemographic and clinical data and found no significant difference in the general data between the two groups after analysis ($P > 0.05$); see Table 1.

2.4. Moral Consideration. This study met the principles of the *Declaration of Helsinki* [14] and was approved by the hospital ethics committee. After enrollment, the research team explained the study purpose, significance, content, and confidentiality to the patients and asked them to sign the informed consent.

2.5. Exit Criteria. Judged by the research team, the patients with the following conditions were unsuitable to continuously participate in the experiment, and their medical records would be kept but not for data analysis: (1) the patients experienced adverse events or serious adverse events; (2) the patients had disease deterioration during the experiment; (3) the patients experienced severe comorbidities or complications; and (4) the patients who were unwilling to continue the clinical trial and requested for quitting the study during the experiment.

2.6. Methods. All patients were treated with neoadjuvant intraarterial chemotherapy, especially as follows: Seldinger technique was adopted to perform percutaneous puncture and intubation on one side of the femoral artery and insert a 5F catheter into the arteria iliaca communis. According to the tumor location and blood supply shown by the arterial angiography, the corresponding uterine artery was selected, and the catheter was retained to connect the infusion pump for continuous arterial infusion for 5 days. The patients daily received 20 mg of cisplatin (Qilu Pharmaceutical Co., Ltd.; National Medical Products Administration approval No. H20023460) mixed with 2000 mg of normal saline, and 10 mg of Adriamycin (Pfizer Wuxi Pharmaceutical Co., Ltd.; National Medical Products Administration approval No. H20013334) mixed with 500 ml of normal saline, with an infusion rate of 110 ml/h. In addition, the patients were daily given 3000 ml of 5% glucose saline for hydration, making the patients' daily urine volume more than 2000 ml. The angiography was performed again after chemotherapy, and then extubation was performed. Surgery was performed at 3–4 weeks depending on the patients' condition.

At the same time, the experimental group was treated with Jianpi xiaoai recipe consisting of 15 g of ginseng, 15 g of radix curcumae, 15 g of poria, 20 g of astragalus, 20 g of oldenlandia, 20 g of sculellaria barbata, 6 g of fructus aurantii, 6 g of liquorice, 10 g of rhizoma pinellinae praeparata,

TABLE 1: Comparison of patient general data.

Items	Experimental group ($n = 60$)	Control group ($n = 60$)	χ^2/t	P
Age (years old)				
Range	28–70	27–68		
Average age	54.68 ± 5.21	54.56 ± 5.23	0.126	0.900
Pathological types				
Adenocarcinoma	52	50	0.261	0.609
Clear cell carcinoma	6	8	0.324	0.570
Adenoacanthoma	2	2	0.000	1.000
Muscular infiltration			0.135	0.714
Superficial muscular infiltration	26	28		
Deep myometrial invasion	34	32		
FIGO clinical stages				
I	12	14	0.196	0.658
II	32	30	0.134	0.715
II	16	16	0.000	1.000
Cytologic grades				
High differentiation	27	26	0.034	0.854
Middle differentiation	21	23	0.144	0.705
Poor differentiation	12	11	0.054	0.817
Menopause			0.035	0.853
Yes	35	36		
No	25	24		
Marital status			0.164	0.685
Married	42	44		
Unmarried/divorced/widowed	18	16		
Basic diseases				
Hypertension	20	18	0.154	0.695
Coronary heart disease (CHD)	12	11	0.054	0.817
Diabetes	12	12	0.000	1.000
Pulmonary diseases	13	10	0.484	0.487

and 5 g of epimedium. Radix ophiopogonis and dendrobium were added for patients with dry mouth; Fructus Amomi and bamboo shavings for patients with nausea and vomiting; fried *Evodia ruticarpa*, corydalis tuber, and Radix Paeoniae Alba for patients with gastrointestinal dysfunction; and angelica sinensis and spatholobus stem for those with blood deficiency. Jianpi Xiaoi recipe was decocted in warm water with one dose daily and was taken twice every day. Patients in the experimental group took the decoction for 2 months after the start of the neoadjuvant intraarterial chemotherapy.

2.7. Observation Criteria

- (1) General data: the general data extraction forms were established by the patients, including the in-patient number, name, age, pathological types, muscular infiltration, clinical staging, cytologic grades, menopause or not, marital status, and basic diseases.
- (2) Short-term efficacy: pelvic CT scan was performed in both groups at 1 month after treatment of the experimental group to evaluate the patient's short-term efficacy according to the response evaluation criteria in solid tumors (RECIST) [15] of the World Health Organization (WHO). The efficacy was classified as complete response (CR, complete endometrial withdrawal, stromal decidualization, and no

endometrial hyperplasia or carcinoma), partial response (PR, reduced grades of endometrial lesions with residual cancer foci accompanied by gland degeneration and atrophy), stable disease (SD, no changes in endometrium with residual cancer foci and no endometrial degeneration and atrophy), and progression disease (PD, the presence of clear muscular infiltration or extrauterine lesions). Objective response rate (ORR) = CR + PR; DCR = CR + PR + SD.

- (3) Immune function indexes: 5 ml of fasting venous blood was extracted from patients in the morning before treatment (T_1), 1 month after treatment (T_2), and 2 months after treatment (T_3). The level of immunoglobulin A (IgA) was detected by rate nephelometry (Shijiazhuang Hipro Biotechnology Corp., Hebei Medical Products Administration certificate no. 20162400132), and the NK, CD4⁺, and CD4⁺/CD8⁺ levels were detected by flow cytometry (ACEA BIO Hangzhou Co., Ltd.; Zhejiang Medical Products Administration certificate no. 20142400581).
- (4) Incidence of adverse reactions: adverse reactions after treatment were evaluated based on the manifestations and grading criteria of acute and subacute adverse reactions [14] of the WHO.

- (5) HUC-1-B cell inhibition rates: 5 ml of fasting venous blood was collected from the patients in the morning before treatment (T_1), 1 month after treatment (T_2), and 2 months after treatment (T_3). Flow cytometry (ACEA BIO Hangzhou Co., Ltd.; Zhejiang Medical Products Administration certificate no. 20142400581) was adopted to detect the apoptosis of HUC-1-B cells.

2.8. Statistical Treatment. In this study, the data were processed by SPSS 20.0 software and graphed by GraphPad Prism 7 (GraphPad Software, San Diego, USA). This study included enumeration data and measurement data, tested by X^2 and t -test. The differences were statistically significant at $P < 0.05$.

3. Results

3.1. Comparison of Patients' General Data. No remarkable differences in general data were observed between the two groups ($P > 0.05$); see Table 1.

3.2. Comparison of Patients' Short-Term Efficacy. The DCR and ORR in the experimental group were higher compared with the control group ($P < 0.05$); see Table 2.

3.3. Comparison of Patients' Immune Function Indexes. The immune function indexes after treatment were remarkably better in the experimental group than in the control group ($P < 0.05$); see Figure 1.

Note: in Figure 1, the abscissa from left to right represented before treatment (T_1), 1 month after treatment (T_2), and 2 months after treatment (T_3). The lines with dots indicated the experimental group, and those with squares indicated the control group. # indicated $P < 0.05$.

Figure 1(a) shows IgA. No statistical difference in IgA at T_1 was found between the two groups (2.64 ± 0.23 vs. 2.68 ± 0.24 , $P > 0.05$). The IgA at T_2 and T_3 in the experimental group was markedly lower than that in the control group (1.68 ± 0.21 vs. 2.25 ± 0.25 , 1.44 ± 0.18 vs. 2.04 ± 0.20 , $P < 0.001$).

Figure 1(b) shows NK. No statistical difference in NK at T_1 was found between the two groups (7.99 ± 0.45 vs. 8.10 ± 0.46 , $P > 0.05$). The NK at T_2 and T_3 in the experimental group was markedly higher than that in the control group (11.13 ± 0.35 vs. 9.21 ± 0.12 , 13.00 ± 0.48 vs. 11.10 ± 0.54 , $P < 0.001$).

Figure 1(c) shows $CD4^+$. No statistical difference in $CD4^+$ at T_1 was found between the two groups (34.58 ± 2.12 vs. 34.64 ± 2.13 , $P > 0.05$). The $CD4^+$ at T_2 and T_3 in the experimental group was remarkably higher than that in the control group (40.68 ± 3.10 vs. 36.57 ± 2.98 , 44.68 ± 3.23 vs. 40.12 ± 3.24 , $P < 0.001$).

Figure 1(d) shows $CD4^+/CD8^+$. No statistical difference in $CD4^+/CD8^+$ at T_1 was found between the two groups (1.24 ± 0.12 vs. 1.23 ± 0.13 , $P > 0.05$). The $CD4^+/CD8^+$ at T_2 and T_3 in the experimental group was remarkably higher

than that in the control group (1.32 ± 0.24 vs. 1.20 ± 0.20 , 1.35 ± 0.24 vs. 1.18 ± 0.21 , $P < 0.05$).

3.4. Comparison of the Incidence of Adverse Reactions. Compared with the control group, the incidence of adverse reactions in the experimental group was notably lower ($P < 0.05$); see Table 3.

3.5. Comparison of HEC-1-B Cell Inhibition Rates. The HEC-1-B cell inhibition rates in the experimental group were remarkably higher compared with the control group ($P < 0.05$); see Figure 2.

Note: in Figure 2, the abscissa from left to right represented before treatment (T_1), 1 month after treatment (T_2), and 2 months after treatment (T_3), and the ordinate represented the HEC-1-B cell inhibition rate (%). The black area was the experimental group and the gray area was the control group. # indicated $P < 0.05$.

No statistical difference in the HEC-1-B cell inhibition rates at T_1 was observed between the two groups (6.98 vs. 6.96 , $P > 0.05$).

The HEC-1-B cell inhibition rates at T_2 and T_3 in the experimental group were remarkably higher compared with the control group (60.24 vs. 40.47 , 72.58 vs. 53.68 , $P < 0.001$).

4. Discussion

EC is a female reproductive systemic malignant tumor with the incidence second only to cervical cancer [16], which is common in perimenopausal women. The early symptoms of EC are nonspecific, and patients may present with symptoms such as abnormal leukorrhea and lumbar-abdominal pain as the disease progresses, seriously threatening their life health. Although the EC incidence has remained high in the past decade, the academic community has not clarified its pathogenesis. Modern Western medicine believes that lifestyle changes, obesity, and hypertension are all high-risk factors for the EC occurrence [17], and the main clinical treatment methods are surgery and chemotherapy. However, surgical treatment alone cannot improve the 5-year survival rate of patients with infiltration of deep muscular layer and lymphatic space [18], so adjuvant chemotherapy is essential. Neoadjuvant intraarterial chemotherapy is often adopted in the treatment of gynecological malignancies such as cervical cancer, which has been proven to inhibit the proliferative activity of cancer cells and accelerate their apoptosis [19]. Although bilateral uterine arteries supply blood for the EC patients, the dominant lateral uterine artery was selected for continuous perfusion in some studies to prolong the contact time between drugs and cancer cells, thereby improving the killing ability of the drugs. To enhance the therapeutic effect, this study also chose unilateral perfusion. After treatment, the HEC-1-B cell inhibition rates of both groups were improved, indicating the efficacy of neoadjuvant chemotherapy in the EC treatment.

Some previous studies have shown that preoperative neoadjuvant intraarterial chemotherapy can reduce the incidence of postoperative complications [20], but the effect

TABLE 2: Comparison of patients' short-term efficacy [n (%)].

Group	CR	PR	SD	PD	ORR	DCR
Experimental group	24 (40.0)	24 (40.0)	10 (16.7)	2 (3.3)	48 (80.0)	58 (96.7)
Control group	16 (26.7)	20 (33.3)	14 (23.3)	10 (16.7)	36 (60.0)	50 (83.3)
X^2	2.400	0.574	0.833	5.926	5.714	5.926
P	0.121	0.449	0.361	0.015	0.017	0.015

FIGURE 1: Comparison of patients' immune function indexes ($\bar{x} \pm s$).TABLE 3: Comparison of the incidence of adverse reactions [n (%)].

Group	Experimental group ($n = 60$)	Control group ($n = 60$)	X^2	P
Leukopenia				
I-II	22 (36.7)	34 (56.7)	4.821	0.028
III-IV	10 (16.7)	22 (36.7)	6.136	0.013
Neutropenia				
I-II	18 (30.0)	30 (50.0)	5.000	0.025
III-IV	6 (10.0)	15 (25.0)	4.675	0.031
Thrombocytopenia				
I-II	5 (8.3)	20 (33.3)	11.368	0.001
III-IV	1 (1.7)	7 (11.7)	4.821	0.028
Decreased hemoglobin				
I-II	12 (20.0)	30 (50.0)	11.868	0.001
III-IV	2 (3.3)	8 (13.3)	3.927	0.048
Nausea and vomiting				
I-II	20 (33.3)	36 (60.0)	8.571	0.003
III-IV	10 (16.7)	22 (36.7)	6.136	0.013
Diarrhea				
I-II	12 (20.0)	24 (40.0)	5.714	0.017
III-IV	2 (3.3)	10 (16.7)	5.926	0.015
Anemia				
I-II	4 (6.7)	12 (20.0)	4.615	0.032
III-IV	0 (0.0)	6 (10.0)	6.316	0.012
Renal dysfunction				
I-II	0 (0.0)	4 (6.7)	4.138	0.042
III-IV	0 (0.0)	4 (6.7)	4.138	0.042

of this chemotherapy regimen on the adverse reactions of EC patients remains unclear. Therefore, reducing the incidence of adverse reactions of patients is the key to improve their quality of life. In recent years, the concept of holistic and dialectical treatment of traditional Chinese medicine (TCM) has achieved remarkable results in the treatment of

malignant tumors. Many studies have confirmed that TCM can improve the immunity of patients with chemotherapy, reduce the destruction of chemotherapy to normal tissues, and curb the further spread of cancer cells [21]. The Jianpi Xiaoi recipe selected in this study is often used in the treatment of colorectal cancer and colon cancer, which can

FIGURE 2: Comparison of HEC-1-B cell inhibition rates.

reduce the hematological and digestive tract adverse reactions of chemotherapy patients and improve the safety of chemotherapy [22]. Although the causes of EC and digestive system malignant tumors are different, TCM classifies them into categories of metrorrhagia and metrostaxis and accumulated diseases that are believed to be caused by dampness-heat and stasis, Qi-stagnation and blood stasis, and stagnation of liver Qi. The herbs in Jianpi Xiaoi recipe have significant effects on them because ginseng, as the principle drug in this recipe can replenish Qi to invigorate the spleen, percolate dampness and disinherit water, and support the healthy energy; astragalus, the minister drug, can benefit Qi and supplement the deficiency; fructus aurantii and radix curcumae can promote Qi, oldenlandia can detoxify the body, rhizoma pinellinae praeparata can dispel dampness, and epimedium can strengthen spleen, in which the five drugs are the assistant drugs. The herbs in the recipe are properly mixed to play the role of removing stasis and eliminating stagnation.

From the perspective of modern pharmacology, ginseng is rich in ginsenoside Rg3 (CS-Rg3) that can effectively inhibit the main pathways for the survival of cancer cells, namely, the activity of PI3K and AKT, and then induce HEC-1-B apoptosis. Wang et al. have found that the combination of cisplatin and astragalus in human endometrial cancer cell line HEC-1-B can significantly improve the lethality of HEC-1-B in vitro, which is stronger than the sum of the two drugs alone, with the cell inhibition rate as 2.7 times that of cisplatin alone [23]. Therefore, the HEC-1-B cell inhibition rates in the experimental group after treatment were significantly higher compared with the control group ($P < 0.05$). In addition to HEC-1-B, the progesterone contained in *Astragalus* can also enhance the immune function of patients, so the experimental group had a lower incidence of adverse reactions and significantly better immune function indexes after treatment compared with the control group ($P < 0.05$). Moreover, *poria* can affect the expression of caspase-3 and Bcl-2, in which caspase-3 can lead to cell apoptosis while Bcl-2 can inhibit apoptosis. A study has shown that *poria* decoction for nude mice bearing

EC can upregulate caspase-3 and downregulate Bcl-2 [24], indicating that *poria* have a positive effect on serum factor levels of EC patients. Therefore, in this study, the DCR and ORR in the experimental group were remarkably higher compared with the control group ($P < 0.05$). It is worth noting that the effect of the herbs in Jianpi Xiaoi recipe on the molecular level of EC patients needs to be further investigated.

In conclusion, Jianpi Xiaoi recipe combined with cisplatin and Adriamycin can increase the HEC-1-B cell inhibition rate in EC patients, improve their immune function, reduce the possibility of adverse reactions, and enhance the therapeutic effect, which is worthy of clinical application and popularization.

Data Availability

Data to support the findings of this study are available on reasonable request from the corresponding author.

Conflicts of Interest

The authors have no conflicts of interest to declare.

References

- [1] H. Nomura, D. Aoki, H. Michimae et al., "Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression: a randomized clinical trial," *JAMA Oncology*, vol. 5, no. 6, pp. 833–840, 2019.
- [2] G. E. Pennacchio, M. E. Cordoba, and M. E. Guerrero-Gimenez, "Abstract P2-05-07: differential expression and localization of beta-catenin and HSP27 after cisplatin/doxorubicin treatment in triple negative breast cancer cells," *Cancer Research*, vol. 79, 2019.
- [3] S. Akhil, M. Katherine, R. Rachel, D. N. Dhanasekaran, Y. D. Zhao, and R. Ramesh, "A non-invasive liquid biopsy screening of urine-derived exosomes for miRNAs as biomarkers in endometrial cancer patients," *The AAPS Journal*, vol. 20, no. 5, p. 82, 2018.
- [4] S. J. Kitson, V. N. Sivalingam, M. Lunt et al., "The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: a prospective case control study," *Gynecologic Oncology An International Journal*, vol. 148, no. 1, pp. 154–160, 2018.
- [5] S. J. Kitson, J. Lindsay, V. N. Sivalingam et al., "The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: a prospective case control study," *Gynecologic Oncology*, vol. 148, no. 1, pp. 154–160, 2018.
- [6] S. de Boer, M. E. Powell, L. Mileschkin et al., "Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial," *The Lancet Oncology*, vol. 19, p. 295, 2018.
- [7] G. Khadra, H. Donkers, A. Bryant, and A. D. Lopes, "Laparoscopy versus laparotomy for the management of early stage endometrial cancer," *Cochrane Database of Systematic Reviews*, vol. 10, no. 10, 2018.
- [8] D. Nasioudis, E. McMinn, E. Ko, A. Haggerty, R. Giuntoli, L. Cory et al., "Role of adjuvant chemotherapy for patients with FIGO stage I high-intermediate risk endometrial

- carcinoma with lymph-vascular invasion," *Gynecologic Oncology*, vol. 162, pp. S267–S268, 2021.
- [9] G. F. Konings, K. M. Cornel, S. Xanthouleas et al., "Blocking 17β -hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach," *The Journal of Pathology*, vol. 244, no. 2, pp. 203–214, 2018.
 - [10] T. Thüner, C. Lange, J. Jauckus, T. Strowitzki, and A. Germeyer, "P-288 Changes in gene and protein expression in human endometrial cancer cell lines after low dose metformin treatment over time," *Human Reproduction*, vol. 36, no. 1, 2021.
 - [11] S. Sugandha, S. Yang, B. Prayes, and S. B. Mukunda, "Current role and benefits of sentinel lymph node mapping in endometrial cancer," *Open Journal of Obstetrics and Gynecology*, vol. 10, no. 4, pp. 478–492, 2020.
 - [12] Q. XiangJun, C. XinRong, M. JiaHao et al., "Analysis of prescription regularity of traditional Chinese medicine for colorectal cancer based on data mining," *China Journal of Chinese Materia Medica*, vol. 46, no. 15, 2021.
 - [13] R. Garcia, A. Hanlon, W. Small et al., "The relationship between body mass index and sexual function in endometrial cancer," *Oncology Nursing Forum*, vol. 45, no. 1, pp. 25–32, 2018.
 - [14] B. M. Fonseca, G. Correia-da-Silva, and N. A. Teixeira, "Cannabinoid-induced cell death in endometrial cancer cells: involvement of TRPV1 receptors in apoptosis," *Journal of Physiology and Biochemistry*, vol. 74, no. 2, pp. 261–272, 2018.
 - [15] S. Taurin, C.-H. Yang, M. Reyes et al., "Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model," *International Journal of Gynecological Cancer*, vol. 28, no. 1, pp. 152–160, 2018.
 - [16] S. Corinne, D. Vries, E. Susan, and R. D. T. Farmer, "Tibolone and endometrial cancer: a cohort and nested case-control study in the UK," *Drug Safety*, vol. 28, no. 3, pp. 241–249, 2018.
 - [17] A. A. Gockley, D. L. Kolin, C. S. Awtrey, N. I. Lindeman, U. A. Matulonis, and P. A. Konstantinopoulos, "Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor," *Gynecologic Oncology*, vol. 150, no. 2, pp. 219–226, 2018.
 - [18] B. Geppert, C. Lonnerfors, M. Bollino, and J. Persson, "Sentinel lymph node biopsy in endometrial cancer-Feasibility, safety and lymphatic complications," *Gynecologic Oncology An International Journal*, vol. 148, no. 3, pp. 491–498, 2018.
 - [19] M. Yoshimoto, A. Tokuda, K. Nishiwaki, K. Sengoku, and Y. Yaginuma, "Abnormal expression of PICT-1 and its codon 389 polymorphism is a risk factor for human endometrial cancer," *Oncology*, vol. 95, no. 1, pp. 43–51, 2018.
 - [20] N. Ogane, M. Yasuda, H. Kato et al., "Cleaved caspase-3 expression is a potential prognostic factor for endometrial cancer with positive peritoneal cytology," *Cytopathology Official Journal of the British Society for Clinical Cytology*, vol. 29, no. 3, pp. 254–261, 2018.
 - [21] L. H. P. Parsons, R. Pedersen, D. L. Richardson, and K. A. Kho, "The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications," *European Journal of Obstetrics & Gynecology and Reproductive Biology*, vol. 223, pp. 108–112, 2018.
 - [22] A. Mills, S. Zadeh, E. Sloan, Z. Chinn, S. C. Modesitt, and K. L. Ring, "Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas," *Modern Pathology*, vol. 31, no. 8, pp. 1282–1290, 2018.
 - [23] P. Wang, C. Li, and X. Li, "Complete biosynthesis of the potential medicine icaritin by engineered *Saccharomyces cerevisiae* and *Escherichia coli*," *Science Bulletin*, vol. 66, no. 18, pp. 1906–1961, 2012.
 - [24] X. Qu, H. Gao, J. Zhai et al., "Astragaloside IV enhances cisplatin chemosensitivity in hepatocellular carcinoma by suppressing MRP2," *European Journal of Pharmaceutical Sciences*, vol. 148, p. 105325, 2020.